Dogwood Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Dogwood Therapeutics Inc's ROI in the second quarter of 2026?
Dogwood Therapeutics Inc recorded a cumulative net loss of $-36 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -41.57%.

Within the Healthcare sector 254 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2899 to 3475.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	23.29 %	91.94 %	273.67 %	3405.75 %	1859.01 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	78	93	87	89	95
Return On Investment (TTM)	-41.57 %	-31.12 %	-38.84 %	-43.25 %	-37.7 %
DWTX's Overall Ranking	# 3475	# 2899	# 3203	# 3157	# 2930
Seq. Investment Change TTM	-4.71 %	-0.48 %	-1.09 %	31.44 %	48.34 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-36	-28	-36	-40	-27

DWTX Company Profile >> Back to DWTX Roi Comparisons >> See Annual DWTX Return On Investment

Return On Investment DWTX's Ranking
Within:	No.
Industry	# 89
Sector	# 255
Overall	# 3475

Return On Investment Statistics
High	Average	Low
-31.12 %	-83.47 %	-174.09 %
(Mar 31 2026)		(Sep 30 2024)

Financial Statements
Dogwood Therapeutics Inc's II. Quarter Investments	$ 78 Millions	DWTX's Balance sheet
Dogwood Therapeutics Inc's II. Quarter Income	$ -12 Millions	Quarterly DWTX's Income Statement
DWTX's Income by Division		See DWTX's Income by Division

DWTX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2020) 2021
Total Investments in Millions	87	91	4	7	30
Y / Y Investment Growth	-4.41 %	2293.87 %	-48.04 %	-75.88 %	-
Net Income in Millions	-36	-13	-5	-12	-10
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-40.77 %	-14.12 %	-139.12 %	-167.17 %	-34.07 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
DWTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for DWTX's Competitors
Subscribers only: Roi for Dogwood Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for DWTX's Customers

Other Ratios
DWTX's Roa	DWTX's Inventory Turnover Ratio	DWTX's Growth Rates	DWTX's Dividend Statistics
	DWTX's Profitability Ratios	DWTX's Asset Turnover Ratio	DWTX's Dividend Growth
DWTX's Roe	DWTX's Valuation Ratios	DWTX's Financial Strength Ratios	DWTX's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-08T17:30:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.